Replies to post #216470 on Biotech Values

[DewDiligence]

APOP has very little trading volume on Nasdaq. The “average volume” figure is badly skewed by the 3.8M shares traded on 1/4/17, when APOP rose 27% on the heels of an “n=3” PR purporting to show proof of concept:

https://finance.yahoo.com/news/cellect-announces-breakthrough-clinical-results-124500349.html

If one were so inclined, it might be possible to accumulate a sizable position over time, but it would be tough to unload if things didn’t work out.

I don’t have an educated opinion on the company’s technology. If anyone does, please post.

[DewDiligence]

APOP—(+37%)—reverse-merges_into_(private) Quoin Pharmaceuticals:

https://finance.yahoo.com/news/cellect-biotechnology-quoin-pharmaceuticals-announce-212600465.html

Under the terms of the Agreement, Cellect shareholders will retain approximately 25% of the combined shares before investment while the shareholders of Quoin will receive shares of Cellect common stock representing approximately 75% of the pre-investment number of shares.

… Quoin is a privately held specialty pharmaceutical company with a portfolio of development stage products addressing major unmet medical needs in rare and orphan diseases. The company’s lead products are under development for a number of rare skin diseases including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Epidermolysis Bullosa.